Abstract
BACKGROUND Although modern minimally invasive vitreoretinal surgery has improved visual outcomes, post-operative proliferative vitreoretinopathy (PVR) and hypotony remain a cause of poor visual results1,2. The migration and proliferation of retinal pigment epithelial cells and the invading immune cells lead to the formation of adherent membranes3. To prevent worsening of PVR and suppress intraocular inflammation, intravitreal triamcinolone, or in some cases, anti-vascular endothelial growth factor (anti-VEGF) have been used4,5. In cases of chronic hypotony, intravitreal triamcinolone injection is also thought to have a role in treatment2.
